Search results with tag "Prescribing information warning"
See full prescribing information for complete boxed ...
labeling.bayerhealthcare.com3 FULL PRESCRIBING INFORMATION WARNING: HEPATOTOXICITY • Severe and sometimes fatal hepatotoxicity has occurred in clinical trials [see Warnings and Precautions (5.1)]. • Monitor hepatic function prior to and during treatment [see Warnings and Precautions (5.1)]. • Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.pharma.us.novartis.comFULL PRESCRIBING INFORMATION WARNING: QT PROLONGATION AND SUDDEN DEATHS Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies (5.2).
HIGHLIGHTS OF PRESCRIBING INFORMATION Co-administration ...
www.merck.com3 FULL PRESCRIBING INFORMATION WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination
HIGHLIGHTS OF PRESCRIBING INFORMATION AUBAGIO
products.sanofi.usFULL PRESCRIBING INFORMATION WARNING: HEPATOTOXICITY and RISK OF TERATOGENICITY • Hepatotoxicity Severe liver injury including fatal liver failure has been reported in patients treated with
Full Prescribing Information including Boxed …
products.sanofi.usFULL PRESCRIBING INFORMATION WARNING: RISK OF SERIOUS INFECTIONS PatientstreatedwithKEVZARAareatincreasedriskfordevelopingseriousinfectionsthat
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.novo-pi.comVICTOZA ® 2 FULL PRESCRIBING INFORMATION WARNING: RISK OF THYROID C−CELL TUMORS • Liraglutide causes dose-dependent and …
HIGHLIGHTS OF PRESCRIBING INFORMATION o For patients with ...
docs.boehringer-ingelheim.comfull prescribing information warning: (a) premature discontinuation of pradaxa increases the risk of thrombotic events, and (b) spinal/epidural hematoma
US-19233 ------------------------- DOSAGE AND ...
www.azpicentral.comFULL PRESCRIBING INFORMATION WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS A. BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding (5.1, 6.1).